Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q4 EPS of ($0.56), $0.11 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.